Histopathological and immunohistochemical characterization of canine prostate cancer

Prostate

Volumn 68, Issue 5, 2008, Pages 477-488

  Lai, Chen Li ^a,b   Van Den Ham, René ^a   Van Leenders, Geert ^c   Van Der Lugt, Jaco ^b   Mol, Jan A ^b   Teske, Erik ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Animal model; Growth pattern; PSMA

Indexed keywords

CYTOKERATIN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 7; HIGH MOLECULAR WEIGHT CYTOKERATIN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; UROPLAKIN;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL SIGNIFICANCE; TISSUE DIFFERENTIATION; TISSUE SPECIFICITY;

ANIMALS; ANTIGENS, SURFACE; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; GLUTAMATE CARBOXYPEPTIDASE II; KERATIN-14; KERATIN-18; KERATIN-5; KERATIN-7; KERATINS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 41849119181     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20720     Document Type: Article

References (46)

1. Waters DJ, Patronek GJ, Bostwick DG, Glickman LT. Comparing the age at prostate cancer diagnosis in humans and dogs. J Natl Cancer Inst 1996;88(22):1686-1687.
2. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases. Prostate 2000;45(2):173-183.
3. Waters DJ, Sakr WA, Hayden DW, Lang CM, McKinney L, Murphy GP, Radinsky R, Ramoner R, Richardson RC, Tindall DJ. Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998;36(1):64-67.
4. Owen LN. TNM classification of tumors in domestic animals, Ed. 1 34 World Health Organization Geneva 1980.
5. Bell FW, Klausner JS, Hayden DW, Feeney DA, Johnston SD. Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987). J Am Vet Med Assoc 1991;199(11):1623-1630.
6. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
7. Robinson EJ, Neal DE, Collins AT. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate 1998;37(3):149-160.
8. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: In vitro and in vivo characterization. Prostate 2003;55(3):206-218.
9. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: Stem cell biology. Urology 2003;62 (5 Suppl 1):11-20.
10. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80(8):1251-1258.
11. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003;162(5):1529-1537.
12. van Leenders GJ, Schalken JA. Epithelial cell differentiation in the human prostate epithelium: Implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 2003;46 (Suppl):S3-S10.
13. Mahapokai W, Xue Y, van Garderen E, van Sluijs FJ, Mol JA, Schalken JA. Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. Prostate 2000;44(1):40-48.
14. Leav I, Schelling KH, Adams JY, Merk FB, Alroy J. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001;48(3):210-224.
15. Teske E, Naan EC, van Dijk EM, van Garderen E, Schalken JA. Canine prostate carcinoma: Epidemiological evidence of an increased risk in castrated dogs. Mol Cell Endocrinol 2002;197(1-2):251-255.
16. LeRoy BE, Nadella MV, Toribio RE, Leav I, Rosol TJ. Canine prostate carcinomas express markers of urothelial and prostatic differentiation. Vet Pathol 2004;41(2):131-140.
17. Sorenmo KU, Goldschimdt M, Shofer F, Goldkamp C, Ferracone J. Immunohistochemical characterization of canine prostatic carcinoma and correlation with castration status and castration time. Vet Compar Oncol 2003;1(1):48-56.
18. Aggarwal S, Ricklis RM, Williams SA, Deanmeade SR. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. Prostate 2006;66(9):903-910.
19. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30(9):36.
20. Grieco V, Patton V, Romussi S, Finazzi M. Cytokeratin and vimentin expression in normal and neoplastic canine prostate. J Comp Pathol 2003;129(1):78-84.
21. Young RH, Srigley JR, Amin MB, Ulbright TM, Cubilla AL. Atlas of tumor pathology. Tumors of the prostate gland, seminal vesicles, male urethra, and penis. Armed Forces Institute of Pathology. Washington 2000; 69-288.
22. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: Pathologic criteria and clinical significance. Mod Pathol 1997;10(6):612-629.
23. Kondo I, Miura T, Fujinami K, Satomi Y, Ida T, Ishizuka E, Uemura H, Noguchi S, Kubota Y, Hosaka M, Harada M. Comparative histological analysis of needle biopsy specimens, prostatectomized specimens and metastatic lymph nodes in prostatic adenocarcinoma - On the basis of the WHO histological classification. Hinyokika Kiyo 1997;43(2):97-101.
24. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004;64(24):9209-9216.
25. McEntee M, Isaacs W, Smith C. Adenocarcinoma of the canine prostate: Immunohistochemical examination for secretory antigens. Prostate 1987;11(2):163-170.
26. Bjartell A, Paju A, Zhang WM, Gadaleanu V, Hansson J, Landberg G, Stenman UH. Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate 2005;64(1):29-39.
27. Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002;117(3):471-477.
28. Xiao Q, Yin H, Lu Z, Meng K, Zhou X. Gleason histologic grading of prostate carcinoma in relation to serum PSA, PSA in situ and immunohistochemical expression of 34 beta E12 and P504S. Zhonghua Nan Ke Xue 2004;10(5):362-365.
29. Aumuller G, Seitz J, Lilja H, Abrahamsson PA, von der Kammer H, Scheit KH. Species- and organ-specificity of secretory proteins derived from human prostate and seminal vesicles. Prostate 1990;17(1):31-40.
30. Anidjar M, Villette JM, Devauchelle P, Delisle F, Cotard JP, Billotey C, Cochand-Priollet B, Copin H, Barnoux M, Triballeau S, Rain JD, Fiet J, Teillac P, Berthon P, Cussenot O. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001;46(1):2-10.
31. Bell FW, Klausner JS, Hayden DW, Lund EM, Liebenstein BB, Feeney DA, Johnston SD, Shivers JL, Ewing CM, Isaacs WB. Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. J Vet Intern Med 1995;9(3):149-153.
32. Karr JF, Kantor JA, Hand PH, Eggensperger DL, Schlom J. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line. Cancer Res 1995;55(11):2455-2462.
33. Olsson AY, Lilja H, Lundwall A. Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen. Genomics 2004;84(1):147-156.
34. Dube JY, Chapdelaine P, Guerin S, Leclerc S, Rennie PS, Matusik RJ, Tremblay RR. Search for androgen response elements in the proximal promoter of the canine prostate arginine esterase gene. J Androl 1995;16(4):304-311.
35. Chapdelaine P, Gauthier E, Ho-Kim MA, Bissonnette L, Tremblay RR, Dube JY. Characterization and expression of the prostatic arginine esterase gene, a canine glandular kallikrein. DNA Cell Biol 1991;10(1):49-59.
36. Lai CL, van den Ham R, van Leenders G, van der Lugt J, Teske E. Comparative characterization of the canine normal prostate in intact and castrated animals, Prostate (in press).
37. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7(5B):927-935.
38. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate 1997;32(2):140-148.
39. Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschwege P, De Nayer P, Van Cangh P, Tombal B. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value? Clin Cancer Res 2000;6(10):4049-4054.
40. van den Ham R, Lai C-L, van Wolferen ME, van Leenen D, Teske E, Mol JA. Canine and human prostate cancer derived cell lines share aberrant signaling pathways (submitted for publication).
41. Parker DC, Folpe AL, Bell J, Oliva E, Young RH, Cohen C, Amin MB. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am J Surg Pathol 2003;27(1):1-10.
42. Ramos Vara JA, Miller MA, Boucher M, Roudabush A, Johnson GC. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors. Vet Pathol 2003;40(1):55-62.
43. Mai KT, Ford JC, Morash C, Gerridzen R. Primary and secondary prostatic adenocarcinoma of the urinary bladder. Hum Pathol 2001;32(4):434-440.
44. Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol 2002;33(11):1136-1140.
45. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, Morii S. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol 1992;421(2):157-161.
46. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001;195(5):563-570.